- Home
- RMCF vs SNGX Comparison
RMCF vs SNGX Comparison
Compare RMCF & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- SNGX
- Stock Information
- Founded
- RMCF 1981
- SNGX 1987
- Country
- RMCF United States
- SNGX United States
- Employees
- RMCF N/A
- SNGX N/A
- Industry
- RMCF Specialty Foods
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- SNGX Health Care
- Exchange
- RMCF Nasdaq
- SNGX Nasdaq
- Market Cap
- RMCF 11.4M
- SNGX 10.1M
- IPO Year
- RMCF N/A
- SNGX 1987
- Fundamental
- Price
- RMCF $2.14
- SNGX $2.76
- Analyst Decision
- RMCF
- SNGX Strong Buy
- Analyst Count
- RMCF 0
- SNGX 1
- Target Price
- RMCF N/A
- SNGX $6.00
- AVG Volume (30 Days)
- RMCF 755.1K
- SNGX 513.1K
- Earning Date
- RMCF 10-14-2025
- SNGX 11-07-2025
- Dividend Yield
- RMCF N/A
- SNGX N/A
- EPS Growth
- RMCF N/A
- SNGX N/A
- EPS
- RMCF N/A
- SNGX N/A
- Revenue
- RMCF $29,545,000.00
- SNGX N/A
- Revenue This Year
- RMCF N/A
- SNGX N/A
- Revenue Next Year
- RMCF N/A
- SNGX N/A
- P/E Ratio
- RMCF N/A
- SNGX N/A
- Revenue Growth
- RMCF 5.81
- SNGX N/A
- 52 Week Low
- RMCF $1.12
- SNGX $1.09
- 52 Week High
- RMCF $3.49
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- RMCF 77.32
- SNGX 48.33
- Support Level
- RMCF $1.64
- SNGX $2.58
- Resistance Level
- RMCF $2.05
- SNGX $2.98
- Average True Range (ATR)
- RMCF 0.13
- SNGX 0.18
- MACD
- RMCF 0.06
- SNGX -0.06
- Stochastic Oscillator
- RMCF 94.81
- SNGX 28.13
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).